EN DE
Watch Medicofarma Biotech SA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medicofarma Biotech SA (MDB) fair value: what the stock is really worth

As of Nov 4, 2026: fair value (intrinsic value) of Medicofarma Biotech SA stock PLN 0.06, price PLN 0.38, that is 84.3% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare PL · ISIN PLINBOK00010

MB Thin data Nov 4, 2026

Medicofarma Biotech SA

MDB · WAR
Very expensive, weak quality

Our calculation puts a fair price 84% below what the stock costs today.

Low debt
Fair value 0.0600 PLN · Strongly overvalued (−84.3%)
Quality 37/100
Weak Growth (revenue 3y −69.6 %/yr in PLN)
Negative free cash flow
Trails peers (1/7)
Narrow moat 3/100 · thin data
Thin data
⚠ Small free float
Watch Medicofarma Biotech SA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

3.76 PLN 0.2400 PLN Fair Value 0.0600 PLN Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range 0.2400 PLN – 3.76 PLN · fair‑value band 0.0400 PLN – 0.0800 PLN · the 0.3820 PLN price screens above the 0.0600 PLN fair value. As of Nov 4, 2026.

Follow Medicofarma Biotech in your weekly email

Every Wednesday you see whether Medicofarma Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medicofarma Biotech SA engages in the research and development of medicines, medicinal products, and biotechnology products in Poland.

Show moreShow less

The company offers staff support and equipment during the early stages of development of generic pharmaceutical products and cosmetics, as well as analytical examinations.

It also provides MediPAN COVID SARS-CoV-2 test, a screening test for detecting the SARS-CoV-2 virus; and real-time PCR genetic tests. The company was formerly known as Inbook Spólka Akcyjna and changed its name to Medicofarma Biotech SA in February 2021.

Medicofarma Biotech SA was founded in 2001 and is headquartered in Warsaw, Poland. Medicofarma Biotech SA operates as a subsidiary of Vitama Spolka Akcyjna.

Stock analysis

Medicofarma Biotech SA (MDB) currently trades at 0.3820 PLN, while our model-based Fair Value estimate is 0.0600 PLN, 84% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the data coverage at low.

Scenario range: 0.0400 PLN (bear) to 0.0800 PLN (bull), the price of 0.3820 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Medicofarma Biotech SA reported revenue of 120K PLN in FY2025 versus 4.3M PLN in FY2022, a compound −69.6%/yr. Reported net income was −2.2M PLN in FY2025.

Key figures

Market cap 26.0M PLN (≈ $6.7M) Micro · EPS (TTM) −0.0300 PLN · Return on equity −40.5% · Return on assets (EBIT) −13.0% · Operating margin −1,909% · Revenue (TTM) 77.9K PLN · Free cash flow −984K PLN.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 32% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −84%, MDB screens richer than that median.

Fair Value models

Bear 0.0400 PLN Fair Value 0.0600 PLN Bull 0.0800 PLN
Price 0.3820 PLN · Downside -84.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 0.0400 PLN 0.0600 PLN 0.0800 PLN 54
All 1 models by family
Asset-Based
NCAV (Graham) 0.0400 PLN 0.0600 PLN 0.0800 PLN 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 12
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 39
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 39
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−90.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−69.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−37.1% (2022) → −1,338.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MDB screens overvalued: fair value 84% below the price. Compare with Merck KGaA →

Compare Medicofarma Biotech SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 552 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −84.3% · Bottom 25%
Profitability
Return on assets −15.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 4.57× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 16
FUTURE (revenue growth)0 · sector 26
PAST (return on equity)0 · sector 28
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $89.20 $110.26 +24% vs MDB
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,773 ₹1,947 +10% vs MDB
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥49.05 ¥53.31 +9% vs MDB
Haleon plc HLN $9.23 $8.59 −7% vs MDB
Merck KGaA MRK €150.45 €109.18 −27% vs MDB
Galderma Group GALD CHF 194.55 CHF 109.26 −44% vs MDB
Takeda Pharmaceutical Company TAK $21.06 $11.34 −46% vs MDB
Teva Pharmaceutical Industries Limited TEVA $41.85 $20.75 −50% vs MDB
Sandoz Group SDZ CHF 82.14 CHF 39.70 −52% vs MDB
Divi's Laboratories Limited DIVISLAB ₹10,038 ₹1,567 −84% vs MDB

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medicofarma Biotech SA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medicofarma Biotech SA Fair Value". https://www.fairvalue-calculator.com/stock/MDB.WAR

Frequently asked questions

Is Medicofarma Biotech SA (MDB) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 0.0600 PLN versus a price of 0.3820 PLN, about 84% lower (overvalued).
What is the fair value of MDB?
Our model-based fair value for Medicofarma Biotech SA is 0.0600 PLN (as of Nov 4, 2026), built from audited fundamentals. The current price: 0.3820 PLN.
What is the quality score of MDB?
Medicofarma Biotech SA has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medicofarma Biotech SA (MDB)?
Our model-based price target is the fair value of 0.0600 PLN (as of Nov 4, 2026) from 1 valuation models. Cautious scenario 0.0400 PLN, optimistic scenario 0.0800 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Medicofarma Biotech SA stock forecast for 2026?
Our models put fair value at 0.0600 PLN, about 84% lower versus a price of 0.3820 PLN (overvalued). Cautious scenario 0.0400 PLN, optimistic scenario 0.0800 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Medicofarma Biotech SA (MDB)?
Medicofarma Biotech SA reported trailing-twelve-month revenue of about 77.9K PLN (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Medicofarma Biotech SA (MDB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medicofarma Biotech SA it is 0.0600 PLN per share (as of Nov 4, 2026), against a price of 0.3820 PLN. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Medicofarma Biotech SA stock overvalued or undervalued in 2026?
As of Nov 4, 2026, MDB trades above its calculated fair value: price 0.3820 PLN, fair value 0.0600 PLN, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MDB?
No. The price is what the market pays today (0.3820 PLN); the fair value is what the company's own numbers justify (0.0600 PLN). For Medicofarma Biotech SA the two are 0.3220 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Medicofarma Biotech SA worth?
The market values Medicofarma Biotech SA at about 26.0M PLN (market capitalisation, as of Nov 4, 2026). Per share that is 0.3820 PLN; our models calculate a fair value of 0.0600 PLN per share.
What do the bullish and bearish scenarios say about MDB?
Our models span a range for Medicofarma Biotech SA: cautious scenario 0.0400 PLN, base 0.0600 PLN, optimistic 0.0800 PLN per share (as of Nov 4, 2026, price 0.3820 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Medicofarma Biotech SA (MDB)?
Balance-sheet figures for Medicofarma Biotech SA (as of Nov 4, 2026): return on equity −40.5%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is MDB from its 52-week high?
Medicofarma Biotech SA trades at 0.3820 PLN, about 32% below its 52-week high of 0.5600 PLN and 14% above the low of 0.3360 PLN (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0600 PLN is for.
Which stocks are comparable to Medicofarma Biotech SA?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medicofarma Biotech SA stock attractive at the current price?
The data as of Nov 4, 2026: price 0.3820 PLN, calculated fair value 0.0600 PLN (−84%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MDB calculated?
We run Medicofarma Biotech SA through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.0600 PLN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0% above its aggregate fair value. Medicofarma Biotech SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medicofarma Biotech SA (MDB)?
The closing price on Nov 4, 2026 was 0.3820 PLN. Our model-based fair value is 0.0600 PLN, about 84% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medicofarma Biotech SA right now?
The price sits above even our optimistic bull case (0.0800 PLN). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (0.0400 PLN to 0.0800 PLN) leaves room in how you read the outcome.

Key figures of Medicofarma Biotech SA

How large is the market capitalisation of Medicofarma Biotech SA (MDB)?
The market capitalisation of Medicofarma Biotech SA is 26.0M PLN (≈ $6.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Medicofarma Biotech SA (MDB)?
Earnings per share at Medicofarma Biotech SA are −0.0300 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Medicofarma Biotech SA (MDB)?
The return on equity (ROE) of Medicofarma Biotech SA is −40.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medicofarma Biotech SA (MDB)?
On an EBIT basis the return on assets of Medicofarma Biotech SA is −13.0% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medicofarma Biotech SA (MDB)?
The operating margin of Medicofarma Biotech SA is −1,909% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Medicofarma Biotech SA (MDB) generate?
The free cash flow of Medicofarma Biotech SA is −984K PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Medicofarma Biotech SA in the live analysis

One click puts Medicofarma Biotech SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.